U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. FDA Technology Transfer Program
  4. Licensing and Collaboration Opportunities
  5. Method of Treating Infectious and Inflammatory Lung Disease with Suppressive Oligonucleotides
  1. Licensing and Collaboration Opportunities

Method of Treating Infectious and Inflammatory Lung Disease with Suppressive Oligonucleotides

Lung disease is the number three killer in America, responsible for one in seven deaths, and lung disease and other breathing problems are the number one killer of babies younger than one year old. Today, more than thirty (30) million Americans are living with chronic inflammatory lung diseases such as emphysema and chronic bronchitis. In addition, approximately one hundred and fifty thousand (150,000) Americans are affected by acute respiratory distress syndrome (ARDS) each year.

Many lung diseases are associated with lung inflammation. For example, ARDS involves the rapid onset of progressive malfunction of the lungs, and is usually associated with the malfunction of other organs due to the inability to take up oxygen. The condition is associated with extensive lung inflammation and small blood vessel injury in all affected organs. ARDS is commonly precipitated by trauma, sepsis (systemic infection), diffuse pneumonia, and shock. It also may be associated with extensive surgery, and certain blood abnormalities. In many cases of ARDS and other inflammatory lung diseases, the inflammatory response that accompanies the underlying disease state is much more dangerous than the underlying infection or trauma.

This application claims use of suppressive oligonucleotides to suppress lung inflammation. More specifically, the application claims use of suppressive oligonucleotides for the treatment, prevention, or inhibition of pneumonia, ARDS, and chronic bronchitis.

Potential Commercial Applications:

Vaccine adjuvants, production of vaccines, immunotherapeutics

Competitive Advantages:



Dennis Klinman
Hiroshi Yamada

Intellectual Property:
U.S. Pat: No. 8,043,622 issued 2011-10-25
U.S. Pat: No. 8,501,188 issued 2013-08-06
U.S. Pat: No. 9,006,203 issued 2015-04-14

Collaboration Opportunity:
The National Cancer Institute, Laboratory of Experimental Immunology, Immune Modulation Group, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.

Licensing Contact:
Bill Ronnenberg, JD-MIP, MS
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4214
Silver Spring, MD 20993
Email: FDAInventionlicensing@fda.hhs.gov
Phone: 240-402-4561

OTT Reference No: E-183-2002/0
Updated: August 9, 2015